Cargando…
ET-1 Translational research platform for malignant brain tumors
Introduction: The standard therapy for malignant brain tumors includes surgery and combination therapy with radiation and chemotherapy, but to provide individualized treatment based on the biological and molecular genetic background of the tumor, integrate genetic information with various functional...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648230/ http://dx.doi.org/10.1093/noajnl/vdab159.014 |
_version_ | 1784610762488020992 |
---|---|
author | Tateishi, Kensuke Miyake, Yohei Nakamura, Taishi Sasame, Jo Hayashi, Takahiro Oshima, Akito Honma, Hirokuni Ikegaya, Naoki Yamamoto, Tetsuya |
author_facet | Tateishi, Kensuke Miyake, Yohei Nakamura, Taishi Sasame, Jo Hayashi, Takahiro Oshima, Akito Honma, Hirokuni Ikegaya, Naoki Yamamoto, Tetsuya |
author_sort | Tateishi, Kensuke |
collection | PubMed |
description | Introduction: The standard therapy for malignant brain tumors includes surgery and combination therapy with radiation and chemotherapy, but to provide individualized treatment based on the biological and molecular genetic background of the tumor, integrate genetic information with various functional data are required. In this study, we present an overview of our integrated approaches for translational research and clinical management. Methods: In glioma, pre-and intra-operative clinical information, including intraoperative genetic diagnosis, and intraoperative rapid immunohistochemistry is obtained, then a multidisciplinary treatment approach is started based on these integrated data. Specimens collected intraoperatively are cryopreserved for future analysis, and primary cultured cells are routinely collected. The cultured cells are transplanted into the brain of immunodeficient mice to establish patient-derived xenograft model (PDX). Genetic screening, such as IDH, TERT, BRAF, H3F3A mutation and MGMT methylation analysis are routinely assessed within a few days after surgery and used as information for integrated diagnosis. In case of PDX establishment or recurrence, we perform whole exon sequencing or comprehensive genomic assessment to identify genetic abnormalities. If genomic alterations for possible molecular targeted therapy are identified, we assess drug sensitivity test in vitro and in vivo, which are utilized for research to develop optimal molecular targeted therapy. The results, such as the therapeutic effects of molecular targeted drugs, are used for clinical applications. Results: Since the platform was established, we have treated a total of 286 patients, including 189 gliomas and 37 central nervous system lymphomas based on the integrated information. We are currently collecting clinical data to examine if this integrated approach could provide clinical benefit.Conclusion: The translational research system for malignant brain tumors plays an important role in the promotion of clinical and basic research. |
format | Online Article Text |
id | pubmed-8648230 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-86482302021-12-07 ET-1 Translational research platform for malignant brain tumors Tateishi, Kensuke Miyake, Yohei Nakamura, Taishi Sasame, Jo Hayashi, Takahiro Oshima, Akito Honma, Hirokuni Ikegaya, Naoki Yamamoto, Tetsuya Neurooncol Adv Supplement Abstracts Introduction: The standard therapy for malignant brain tumors includes surgery and combination therapy with radiation and chemotherapy, but to provide individualized treatment based on the biological and molecular genetic background of the tumor, integrate genetic information with various functional data are required. In this study, we present an overview of our integrated approaches for translational research and clinical management. Methods: In glioma, pre-and intra-operative clinical information, including intraoperative genetic diagnosis, and intraoperative rapid immunohistochemistry is obtained, then a multidisciplinary treatment approach is started based on these integrated data. Specimens collected intraoperatively are cryopreserved for future analysis, and primary cultured cells are routinely collected. The cultured cells are transplanted into the brain of immunodeficient mice to establish patient-derived xenograft model (PDX). Genetic screening, such as IDH, TERT, BRAF, H3F3A mutation and MGMT methylation analysis are routinely assessed within a few days after surgery and used as information for integrated diagnosis. In case of PDX establishment or recurrence, we perform whole exon sequencing or comprehensive genomic assessment to identify genetic abnormalities. If genomic alterations for possible molecular targeted therapy are identified, we assess drug sensitivity test in vitro and in vivo, which are utilized for research to develop optimal molecular targeted therapy. The results, such as the therapeutic effects of molecular targeted drugs, are used for clinical applications. Results: Since the platform was established, we have treated a total of 286 patients, including 189 gliomas and 37 central nervous system lymphomas based on the integrated information. We are currently collecting clinical data to examine if this integrated approach could provide clinical benefit.Conclusion: The translational research system for malignant brain tumors plays an important role in the promotion of clinical and basic research. Oxford University Press 2021-12-06 /pmc/articles/PMC8648230/ http://dx.doi.org/10.1093/noajnl/vdab159.014 Text en © The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Supplement Abstracts Tateishi, Kensuke Miyake, Yohei Nakamura, Taishi Sasame, Jo Hayashi, Takahiro Oshima, Akito Honma, Hirokuni Ikegaya, Naoki Yamamoto, Tetsuya ET-1 Translational research platform for malignant brain tumors |
title | ET-1 Translational research platform for malignant brain tumors |
title_full | ET-1 Translational research platform for malignant brain tumors |
title_fullStr | ET-1 Translational research platform for malignant brain tumors |
title_full_unstemmed | ET-1 Translational research platform for malignant brain tumors |
title_short | ET-1 Translational research platform for malignant brain tumors |
title_sort | et-1 translational research platform for malignant brain tumors |
topic | Supplement Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648230/ http://dx.doi.org/10.1093/noajnl/vdab159.014 |
work_keys_str_mv | AT tateishikensuke et1translationalresearchplatformformalignantbraintumors AT miyakeyohei et1translationalresearchplatformformalignantbraintumors AT nakamurataishi et1translationalresearchplatformformalignantbraintumors AT sasamejo et1translationalresearchplatformformalignantbraintumors AT hayashitakahiro et1translationalresearchplatformformalignantbraintumors AT oshimaakito et1translationalresearchplatformformalignantbraintumors AT honmahirokuni et1translationalresearchplatformformalignantbraintumors AT ikegayanaoki et1translationalresearchplatformformalignantbraintumors AT yamamototetsuya et1translationalresearchplatformformalignantbraintumors |